{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:07:36Z","timestamp":1773245256755,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.therap.2024.12.013","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T11:08:53Z","timestamp":1737198533000},"page":"546-552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lichenoid drug eruption and apalutamide: Analyses from pharmacovigilance databases and disproportionality analysis"],"prefix":"10.1016","volume":"80","author":[{"given":"Viktoryia","family":"Prontskus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Lise","family":"Pinault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie-Marie","family":"Scailteux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Noelle","family":"Beyens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Fresse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-3178","authenticated-orcid":false,"given":"Nadine","family":"Petitpain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.12.013_bib0125","series-title":"ERLEADA - Summary of Product Characteristics","year":"2024"},{"key":"10.1016\/j.therap.2024.12.013_bib0130","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN Study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.therap.2024.12.013_bib0135","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S1470-2045(18)30456-X","article-title":"Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Saad","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.therap.2024.12.013_bib0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12894-020-00689-0","article-title":"Skin rash following administration of apalutamide in Japanese patients with advanced prostate cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study","volume":"20","author":"Uemura","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.therap.2024.12.013_bib0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2024.12.013_bib0150","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2024.12.013_bib0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/iju5.12331","article-title":"Apalutamide-associated skin rash in patients with prostate cancer: Histological evaluation by skin biopsy","volume":"4","author":"Tohi","year":"2021","journal-title":"IJU Case Rep"},{"key":"10.1016\/j.therap.2024.12.013_bib0160","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/iju5.12525","article-title":"Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer","volume":"5","author":"Honda","year":"2022","journal-title":"IJU Case Rep"},{"key":"10.1016\/j.therap.2024.12.013_bib0165","doi-asserted-by":"crossref","first-page":"1291564","DOI":"10.3389\/fimmu.2023.1291564","article-title":"Case report: apalutamide-induced severe lethal cutaneous adverse effects in China","volume":"14","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.therap.2024.12.013_bib0170","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.annder.2023.09.001","article-title":"A rare and severe lichenoid skin eruption after apalutamide treatment for prostate cancer","volume":"150","author":"Guglielmini","year":"2023","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.therap.2024.12.013_bib0175","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1177\/10781552231180598","article-title":"Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer","volume":"29","author":"Cremante","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.therap.2024.12.013_bib0180","series-title":"Carrefour Pathologie 2020 Histos\u00e9minaire \u00ab\u00a0\u00c0 l\u2019interface derme-\u00e9piderme, des \u201cpatterns\u201d vraiment pas ternes\u00a0\u00bb","author":"Ortonne","year":"2020"},{"key":"10.1016\/j.therap.2024.12.013_bib0185","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.clindermatol.2015.09.006","article-title":"Lichen planus and other lichenoid dermatoses: kids are not just little people","volume":"33","author":"Payette","year":"2015","journal-title":"Clin Dermatol"},{"issue":"5","key":"10.1016\/j.therap.2024.12.013_bib0190","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/jdv.18879","article-title":"Cutaneous lichenoid drug eruptions: a narrative review evaluating demographics, clinical features and culprit medications","volume":"37","author":"Maul","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2024.12.013_bib0195","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2024.12.013_bib0200","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.12.013_bib0205","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1046\/j.0306-5251.2001.01501.x","article-title":"Determinants of signal selection in a spontaneous reporting system for adverse drug reactions","volume":"52","author":"Van Puijenbroek","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.12.013_bib0210","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.12.013_bib0215","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00228-017-2325-0","article-title":"Drug-induced oral lichenoid reactions: a real clinical entity? A systematic review","volume":"73","author":"Fortuna","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.12.013_bib0220","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/1346-8138.16972","article-title":"Characteristics of mild and severe apalutamide-related cutaneous adverse events in patients with prostate cancer: a review of the literature","volume":"51","author":"Katsuta","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.therap.2024.12.013_bib0225","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1021\/acs.chemrestox.9b00247","article-title":"Enzalutamide and apalutamide: in vitro chemical reactivity studies and activity in a mouse drug allergy model","volume":"33","author":"Ji","year":"2020","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.therap.2024.12.013_bib0230","series-title":"XTANDI (enzalutamide) - Summary of Product Characteristics","year":"2024"},{"key":"10.1016\/j.therap.2024.12.013_bib0235","first-page":"132","article-title":"Lichen plan et dermatoses lich\u00e9no\u00efdes","volume":"2","author":"Levy","year":"2005","journal-title":"EMC Dermatol-Cosmetol"},{"key":"10.1016\/j.therap.2024.12.013_bib0240","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of spontaneous reporting of adverse drug reactions in France","volume":"288","author":"B\u00e9gaud","year":"2002","journal-title":"JAMA"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725000186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725000186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:07:48Z","timestamp":1761912468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595725000186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0040595725000186"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.12.013","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lichenoid drug eruption and apalutamide: Analyses from pharmacovigilance databases and disproportionality analysis","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}